{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:36:45Z","timestamp":1786113405461,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ruxolitinib cream has demonstrated efficacy and safety in patients aged \u2265\u20092\u00a0years with mild to moderate atopic dermatitis (AD) in clinical trials. Early real-world data have demonstrated results consistent with clinical trial observations and have indicated that initiation of ruxolitinib cream may reduce the need for other AD therapies, both topical and systemic. This analysis investigated the longer-term (18-month) effect of ruxolitinib cream on AD treatment patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective, observational study, US claims data from the Healthcare Integrated Research Database (HIRD\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) were used to identify new ruxolitinib cream users aged \u2265\u200912\u00a0years between October 1, 2021 and July 31, 2022. The 6\u00a0months prior to the index date (first claim for ruxolitinib cream) comprised the baseline period. The 18-month follow-up period was divided into months\u00a01\u20136, 7\u201312, and 13\u201318 to evaluate short- and long-term effects of ruxolitinib cream on AD treatment patterns.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1269 patients were included in the analysis. The mean (SD; range) number of ruxolitinib cream fills during the 18-month follow-up period was 2.4 (2.3; 1\u201319). By months\u00a013\u201318 of follow-up, claims for topical corticosteroids, topical calcineurin inhibitors, and topical PDE4 inhibitors were reduced from baseline by 52%, 63%, and 70%, respectively. Use of oral corticosteroids was reduced by 28%, with a 32% reduction in the mean cumulative prednisone-equivalent dose. Among patients with baseline biologic AD therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009231), 35.5% did not receive biologics during months\u00a013\u201318 of follow-up. Additionally, among patients without baseline biologic use (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091038), &gt;\u200990% remained off biologics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Use of both topical and systemic AD therapies, including biologics, decreased over 18\u00a0months following initiation of ruxolitinib cream. These data suggest that ruxolitinib cream may reduce the need for additional topical therapies and limit escalation to systemic therapies for adults and adolescents with AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12325-026-03670-9","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:39:07Z","timestamp":1785911947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effect of Ruxolitinib Cream: Decreased Use of Additional Topical Therapies and Limited Escalation to Systemic Treatments"],"prefix":"10.1007","author":[{"given":"Jinan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6108-4154","authenticated-orcid":false,"given":"Karishma","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6473-6469","authenticated-orcid":false,"given":"Vincent","family":"Willey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sturm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"issue":"10478","key":"3670_CR1","doi-asserted-by":"publisher","first-page":"P583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):P583\u201396.","journal-title":"Lancet"},{"issue":"3","key":"3670_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"3670_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.anai.2018.12.017","volume":"122","author":"J Chung","year":"2019","unstructured":"Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(4):360\u20136.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"3670_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393.","journal-title":"Allergy"},{"issue":"3","key":"3670_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583\u201390.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"3670_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417\u201328.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3670_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3670_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.0906-6705.2006.00435.x","volume":"15","author":"S Schoepe","year":"2006","unstructured":"Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406\u201320.","journal-title":"Exp Dermatol"},{"issue":"2","key":"3670_CR9","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"3670_CR10","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/jdv.20639","volume":"39","author":"A Wollenberg","year":"2025","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European Guideline (EuroGuiDerm) on atopic eczema: living update. J Eur Acad Dermatol Venereol. 2025;39(9):1537\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"15","key":"3670_CR11","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood"},{"issue":"7","key":"3670_CR12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/pharmaceutics13071044","volume":"13","author":"P Smith","year":"2021","unstructured":"Smith P, Yao W, Shepard S, et al. Developing a JAK inhibitor for targeted local delivery: ruxolitinib cream. Pharmaceutics. 2021;13(7):1044.","journal-title":"Pharmaceutics"},{"key":"3670_CR13","unstructured":"Opzelura\u00ae (ruxolitinib cream). Full Prescribing Information. Wilmington, DE: 2025."},{"issue":"3","key":"3670_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaad.2025.05.1385","volume":"93","author":"LF Eichenfield","year":"2025","unstructured":"Eichenfield LF, Stein Gold LF, Simpson EL, et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11\u00a0years with atopic dermatitis: results from TRuE-AD3, a phase\u00a03, randomized double-blind study. J Am Acad Dermatol. 2025;93(3):689\u201398.","journal-title":"J Am Acad Dermatol"},{"key":"3670_CR15","unstructured":"Eichenfield LF, Stein Gold LF, Simpson EL, et al. 52-week safety and disease control with ruxolitinib cream in children aged 2\u201311\u00a0years with atopic dermatitis: results from the phase\u00a03 TRuE-AD3 study. Presented at: 33rd European Academy of Dermatology and Venereology (EADV) Congress; September 25\u201328, 2024; Amsterdam, the Netherlands."},{"issue":"5","key":"3670_CR16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase\u00a03 studies. J Am Acad Dermatol. 2023;88(5):1008\u201316.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3670_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase\u00a03, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3670_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-023-00840-1","volume":"25","author":"W Hu","year":"2024","unstructured":"Hu W, Thornton M, Livingston RA. Real-world use of ruxolitinib cream: safety analysis at 1\u00a0year. Am J Clin Dermatol. 2024;25(2):327\u201332.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"3670_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s13555-024-01116-0","volume":"14","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Liu J, Marwaha S, Piercy J, Sturm D, Anderson P. Satisfaction with control of mild to moderate atopic dermatitis with ruxolitinib cream: US physician and patient perspectives. Dermatol Ther (Heidelb). 2024;14(3):685\u201396.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3670_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/CEOR.S506043","volume":"17","author":"J Liu","year":"2025","unstructured":"Liu J, Desai K, Teng CC, et al. Atopic dermatitis treatments before and after initiation of ruxolitinib cream: 6-month follow-up analysis of a US payer claims database. Clinicoecon Outcomes Res. 2025;17:69\u201377.","journal-title":"Clinicoecon Outcomes Res"},{"key":"3670_CR21","doi-asserted-by":"publisher","first-page":"569871","DOI":"10.2147\/CEOR.S569871","volume":"18","author":"J Liu","year":"2026","unstructured":"Liu J, Desai K, Chen HP, et al. Real-world treatment patterns in patients with atopic dermatitis initiating ruxolitinib cream: a 12-month follow-up analysis of a US payer claims database. Clinicoecon Outcomes Res. 2026;18:569871.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"3670_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"issue":"3","key":"3670_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2025.05.1386","volume":"93","author":"DMR Davis","year":"2025","unstructured":"Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol. 2025;93(3):745.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3670_CR24","doi-asserted-by":"publisher","first-page":"A22","DOI":"10.1016\/j.jval.2013.03.135","volume":"16","author":"T Wasser","year":"2013","unstructured":"Wasser T, Wu B, Ycas J, Tunceli O, Cziraky MJ. Comparison of commercial insurance databases to census data for age, gender and geographic region in the United States. Value Health. 2013;16(3):A22\u20133.","journal-title":"Value Health"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03670-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T19:02:27Z","timestamp":1785956547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03670-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":24,"alternative-id":["3670"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03670-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jinan Liu and Daniel Sturm are employees and shareholders of Incyte Corporation. Karishma Desai, Chia-Chen Teng, Peter Chen, and Vincent Willey are employees of Carelon Research, which received funding from Incyte Corporation to perform this research, and are shareholders of Elevance Health, the parent company of Carelon Research.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis used de-identified claims data from a preexisting database and does not contain any new studies with human participants performed by any of the authors; thus, institutional review board approval was not required. The HIRD\n                      \u00ae\n                      is a proprietary database created by Carelon Research. Carelon Research accesses the HIRD\n                      \u00ae\n                      data in a manner that complies with federal and state laws and regulations, including those related to privacy and security of individually identifiable health information.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}